Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Innate Pharma SA ( (FR:IPH) ) has shared an update.
On May 12, 2025, Innate Pharma S.A. announced its total number of shares and voting rights as of May 5, 2025. The company reported 92,176,373 ordinary shares, along with preferred shares from 2016 and 2017, resulting in a total of 92,962,943 theoretical voting rights and 92,944,368 exercisable voting rights. This disclosure aligns with regulatory requirements to keep the market informed, potentially impacting shareholder decisions and market perception.
More about Innate Pharma SA
Innate Pharma S.A. is a global, clinical-stage biotechnology company focused on developing immunotherapies for cancer patients. The company leverages its proprietary ANKET® platform for multi-specific NK Cell Engagers, as well as developing Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs). Innate Pharma collaborates with major biopharmaceutical companies like Sanofi and AstraZeneca to advance research and development.
YTD Price Performance: 5.90%
Average Trading Volume: 168,957
Technical Sentiment Signal: Sell
Current Market Cap: €188.5M
For an in-depth examination of IPH stock, go to TipRanks’ Stock Analysis page.